The purpose of this study is to evaluate the efficacy, safety and tolerability of MBX-102 in combination with allopurinol compared to allopurinol alone when administered orally once a day for four weeks to gout patients with an inadequate hypouricemic response to allopurinol alone.
Read more: http://www.clinicaltrials.gov/ct2/show/NCT01399008?cond=%22Arthritis%22&lup_s=07/14/2011&lup_d=30
